Gsa Capital Partners LLP Black Diamond Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$4.65 - $7.39 $78,185 - $124,255	16,814 New	16,814 $78,000
Q3 2022 Nov 14, 2022	BUY	$1.68 - $4.01 $37,776 - $90,168	22,486 New	22,486 $38,000
Q4 2021 Feb 14, 2022	SELL	$5.18 - $8.48 $358,968 - $587,655	-69,299 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$8.46 - $12.42 $30,007 - $44,053	-3,547 Reduced 4.87%	69,299 $586,000
Q2 2021 Aug 05, 2021	BUY	$12.19 - $28.17 $629,564 - $1.45 Million	51,646 Added 243.61%	72,846 $888,000
Q1 2021 May 10, 2021	BUY	$22.23 - $34.75 $471,276 - $736,700	21,200 New	21,200 $514,000

121

48.8M

1.84M

1.93M

Ticker BDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,339,500
Market Cap $89.4M
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.